Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Friday. $70.43 million flowed into the stock on the tick-up and $123.04 million flowed out of the stock on the tick-down, for a money net flow of $52.61 million out of the stock. Of all equities tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.05 for the day and closed at $34.82

A number of equities analysts have recently issued reports on PFE shares. Jefferies Group set a $41.50 price target on Pfizer and gave the stock a “buy” rating in a research note on Thursday, July 14th. JPMorgan Chase & Co. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 3rd. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target on the stock in a research note on Tuesday, August 2nd. Credit Suisse Group AG restated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research note on Monday, August 22nd. Finally, BMO Capital Markets restated a “buy” rating and issued a $40.00 price target on shares of Pfizer in a research note on Thursday, July 21st. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $38.82.

The company’s 50-day moving average price is $35.84 and its 200-day moving average price is $33.28. The firm has a market cap of $211.21 billion and a PE ratio of 30.87.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. During the same quarter in the prior year, the firm posted $0.56 earnings per share. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.45%.

Other hedge funds and institutional investors have bought and sold shares of the company. Mycio Wealth Partners LLC raised its position in Pfizer by 5.8% in the fourth quarter. Mycio Wealth Partners LLC now owns 33,436 shares of the biopharmaceutical company’s stock worth $1,079,000 after buying an additional 1,825 shares in the last quarter. Midas Management Corp raised its position in Pfizer by 5.5% in the fourth quarter. Midas Management Corp now owns 40,000 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 2,076 shares in the last quarter. Private Capital Management Inc. acquired a new position in Pfizer during the fourth quarter worth approximately $1,298,000. Wellington Shields & Co. LLC raised its position in Pfizer by 17.4% in the fourth quarter. Wellington Shields & Co. LLC now owns 52,579 shares of the biopharmaceutical company’s stock worth $1,697,000 after buying an additional 7,809 shares in the last quarter. Finally, SNS Financial Group LLC raised its position in Pfizer by 9.1% in the fourth quarter. SNS Financial Group LLC now owns 62,206 shares of the biopharmaceutical company’s stock worth $2,008,000 after buying an additional 5,192 shares in the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.